The National Medicines Authority (Infarmed) proceeded with the withdrawal from the market of a batch of the medication Salofalk. The suspension of batch L25428A is due to a serialization deviation identified in the units of the product.
Salofalk is a medication used in the treatment of inflammatory intestinal diseases. The serialization deviation refers to a problem in the individual identification of each unit of the medication, which may compromise the traceability of the product.
Patients currently undergoing treatment with this medication are advised to contact their prescribing doctor before making any changes to their medication. This recommendation aims to ensure the safe continuity of healthcare.
